<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0702221686
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Influvac Tetra
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        A/Brisbane/02/2018 (H1N1),A/Kansas/14/2017 (H3N2),B/Colorado/06/2017,B/Phuket/3073/2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15,15,15,15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        intramuscular, subcutaneous
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        54.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ABBOTT BIOLOGICALS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ABBOTT BIOLOGICALS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBOTT BIOLOGICALS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07BB02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Influvac Tetra is a vaccine. This vaccine helps to protect you or your child<br />against flu (influenza), particularly in subjects who run a high risk of associated<br />complications. Influvac Tetra is prescribed for adults and children from 6 months<br />of age. The use of Influvac Tetra should be based on official recommendations.<br />When a person is given the vaccine Influvac Tetra, the immune system (the<br />body&rsquo;s natural defence system) will produce its own protection (antibodies)<br />against the disease. None of the ingredients in the vaccine can cause flu.<br />Flu is a disease that can spread rapidly and is caused by different types of<br />strains that can change every year. Therefore, this is why you or your child<br />might need to be vaccinated every year. The greatest risk of catching flu is<br />during the cold months between October and March. If you or your child were<br />not vaccinated in the autumn, it is still sensible to be vaccinated up until the<br />spring since you or your child run the risk of catching flu until then. Your doctor<br />will be able to recommend the best time to be vaccinated.<br />Influvac Tetra will protect you or your child against the four strains of virus<br />contained in the vaccine from about 2 to 3 weeks after the injection.<br />The time between infection with flu and illness (incubation period) is a few days,<br />so if you or your child are exposed to flu immediately before or after vaccination,<br />you or your child could still develop the illness.<br />The vaccine will not protect against the common cold, even though some of the<br />symptoms are similar to flu.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>To make sure that Influvac Tetra is suitable for you or your child, it is important<br />to tell your doctor, pharmacist or nurse if any of the points below apply to you or<br />your child. If there is anything you do not understand, ask your doctor,<br />pharmacist or nurse to explain.<br /><strong>Do not use Influvac Tetra</strong><br />- If you or your child are allergic to:<br />&bull; the active substances, or<br />&bull; any of the other ingredients of Influvac Tetra (see section 6), or<br />&bull; any component that may be present in very small amounts such as eggs<br />(ovalbumin (certain type of protein) or chicken proteins), formaldehyde<br />(colourless gas with a pungent odour), cetyltrimethylammonium bromide<br />(chemical substance), polysorbate 80 (oil-like substance used in medicinal and<br />nutritional products) or gentamicin (an antibiotic that is used to treat bacterial<br />infections)<br />- If you or your child have an illness with a high temperature or acute infection,<br />the vaccination shall be postponed until after you or your child have recovered.<br /><strong>Warnings and precautions</strong><br />You or your child should tell your doctor before vaccination if you or your child<br />have<br />- a poor immune response (immunodeficiency or taking medicines affecting the<br />immune system).<br />- a bleeding problem or bruising easily.<br />Your doctor will decide if you or your child should receive the vaccine.<br />Fainting, feeling faint or other stress related reactions can occur following, or<br />even before, any needle injection. Therefore, tell your doctor or nurse if you or<br />your child have experienced this kind of reaction with a previous injection.<br />If, for any reason, you or your child have a blood test within a few days following<br />a flu vaccination, please tell your doctor. This is because false positive blood<br />test results have been observed in a few patients who had recently been<br />vaccinated.<br />As with all vaccines, Influvac Tetra may not fully protect all persons who are<br />vaccinated.<br /><strong>Other medicines and Influvac Tetra</strong><br />- Tell your doctor, pharmacist or nurse if you or your child are taking, have<br />recently taken or might take any other medicines, including medicines obtained<br />without a prescription.<br />- Influvac Tetra can be given at the same time as other vaccines by using<br />another leg or arm. It should be noted that the side effects may be stronger.<br />- The protective (immunological) response may decrease in case of<br />immunosuppressant treatment, such as treatment with corticosteroids<br />(hormones of the adrenal gland, commonly used to reduce inflammation, which<br />may suppress the immune system), cytotoxic drugs (medicines used in<br />chemotherapy) or radiotherapy.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor or pharmacist for advice before taking<br />this medicine.<br />Flu vaccines can be used in all stages of pregnancy. Larger datasets on safety<br />are available for the second and third trimester, compared with the first<br />trimester; however, data from worldwide use of flu vaccines do not indicate that<br />the vaccine would have harmful effects on the pregnancy or the baby.<br />Influvac Tetra may be used during breast-feeding.<br />Your doctor, pharmacist or nurse will be able to decide if you or your child<br />should receive Influvac Tetra. Ask your doctor, pharmacist or nurse for advice<br />before taking any medicine.<br /><strong>Driving and using machines</strong><br />Influvac Tetra has no or negligible influence on the ability to drive or use<br />machines.<br /><strong>Influvac Tetra contains sodium and potassium</strong><br />This vaccine contains less than 1 mmol sodium (23 mg) per dose, i.e.<br />essentially &lsquo;sodium- free&rsquo;.<br />This vaccine contains potassium, less than 1 mmol (39 mg) per dose, i.e.<br />essentially &ldquo;potassium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>Dosage</strong></u><br />Adults receive one 0.5 ml dose.<br /><strong>Use in children</strong><br />Children from 6 months &ndash; 17 years of age receive one 0.5 ml dose.<br />Children less than 9 years of age, who have not previously been vaccinated<br />with a seasonal influenza vaccine: a second dose of 0.5 ml should be given<br />after an interval of at least 4 weeks. Infants less than 6 months of age: the<br />safety and efficacy of Influvac Tetra have not been established.<br /><u><strong>Route(s) and method of administration</strong></u><br />Your doctor or nurse will administer the recommended dose of the vaccine as<br />an injection into the muscle or deep under the skin.<br />If you have any further questions on the use of this product, ask your doctor,<br />pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Influvac Tetra can cause side effects, although not<br />everybody gets them.<br /><strong>See your doctor straight away if you or your child experience any of the<br />following side effects - you or your child may need urgent medical<br />attention.</strong><br />Severe allergic reactions (unknown frequency, occurred occasionally during use<br />of trivalent flu vaccine Influvac)<br />&bull; that may lead to medical emergency with low blood pressure, rapid, shallow<br />breathing, rapid heart rate and weak pulse, cold, clammy skin, dizziness, that<br />may lead to collapse (shock)<br />&bull; swelling most apparent in the head and the neck, including the face, lips,<br />tongue, throat or any other part of the body and which may cause difficulty in<br />swallowing or breathing (angioedema)<br />During clinical trials with Influvac Tetra the following side effects have been<br />observed:<br /><strong>Adults and elderly:</strong><br /><u>Very common: may affect more than 1 in 10 people:</u><br />&bull; headache a<br />&bull; fatigue<br />&bull; local reactions: vaccination site pain<br />a In elderly adults (61 years of age and older) reported as common<br /><u>Common: may affect up to 1 in 10 people:</u><br />&bull; sweating<br />&bull; muscular pain (myalgia), joint pain (arthralgia)<br />&bull; generally feeling unwell (malaise), shivering,<br />&bull; local reactions: redness, swelling, bruising (ecchymosis), hardness<br />(induration) around the area where the vaccine is injected.<br /><u>Uncommon: may affect up to 1 in 100 people:</u><br />&bull; fever<br /><strong>Children (6 months - 17 years of age):<br />Side effects that occurred in children 6 to 35 months of age:</strong><br /><u>Very common: may affect more than 1 in 10 people:</u><br />&bull; drowsiness</p><p>&bull; sweating<br />&bull; appetite loss<br />&bull; diarrhoea, vomiting<br />&bull; irritability/fussiness<br />&bull; fever<br />&bull; local reactions: pain, redness<br /><u>Common: may affect up to 1 in 10 people:</u><br />&bull; local reaction: swelling, induration, ecchymosis<br />Side effects that occurred in children 3 - 5 years of age:<br /><u>Very common: may affect more than 1 in 10 people:</u><br />&bull; drowsiness<br />&bull; appetite loss<br />&bull; irritability/fussiness<br />&bull; local reactions: vaccination site pain, redness, swelling, hardness (induration)<br />around the area where the vaccine is injected<br /><u>Common: may affect up to 1 in 10 people:</u><br />&bull; sweating<br />&bull; diarrhoea, vomiting<br />&bull; fever<br />&bull; local reaction: bruising (ecchymosis)<br />Side effects that occurred in children 6 - 17 years of age:<br /><u>Very common: may affect more than 1 in 10 people:</u><br />&bull; headache<br />&bull; nausea, abdominal pain, diarrhoea, vomiting<br />&bull; muscular pain (myalgia)<br />&bull; fatigue, generally feeling unwell (malaise)<br />&bull; local reactions: vaccination site pain, redness, swelling, hardness (induration)<br />around the area where the vaccine is injected<br /><u>Common: may affect up to 1 in 10 people:</u><br />&bull; sweating<br />&bull; joint pain (arthralgia)<br />&bull; fever<br />&bull; shivering<br />&bull; local reaction: bruising (ecchymosis)</p><p><strong>All age groups</strong><br />For all age groups, most reactions mentioned above usually occurred within the<br />first 3 days following vaccination and resolved spontaneously within 1 to 3 days<br />after onset. The intensity of these reactions was generally mild.<br />Next to the above side effects, the following side effects occurred occasionally<br />during general use of the trivalent influenza vaccine Influvac:<br />Unknown frequency (cannot be estimated from the available data):<br />&bull; skin reactions that may spread throughout the body including itchiness of the<br />skin (pruritus, urticaria), skin rash<br />&bull; blood vessel inflammation which may result in skin rashes (vasculitis) and in<br />very rare cases in temporary kidney problems.<br />&bull; pain situated on the nerve route (neuralgia), anomalies in the perception of<br />touch, pain, heat and cold, fits (convulsions) associated with fever, neurological<br />disorders that may result in stiff neck, confusion, numbness, pain and weakness<br />of the arms or legs, loss of balance, loss of reflexes, paralysis of part or all the<br />body (inflammation of the brain and the spinal cord (encephalomyelitis), nerve<br />inflammation (neuritis), nerve inflammation with sudden onset (Guillain-Barr&eacute;<br />Syndrome))<br />&bull; temporary reduction in the number of certain types of particles in the blood<br />called platelets; a low number of these can result in excessive bruising or<br />bleeding (transient thrombocytopenia); temporary swelling of the glands in the<br />neck, armpit or groin (transient lymphadenopathy)<br /><strong>Reporting of side effects</strong><br />If you or your child get any side effects, talk to your doctor, pharmacist or nurse.<br />This includes any possible side effects not listed in this leaflet.</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)<br />o Fax: +966-11-205-7662<br />o SFDA Call Center: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.<br />Do not use Influvac Tetra after the expiry date which is stated on the carton after<br />EXP. The expiry date refers to the last day of that month.<br />Store Influvac Tetra in a refrigerator (+ 2 &deg;C to + 8 &deg;C). Do not freeze. Store the<br />product in the original package in order to protect from light.<br />Medicines should not be disposed of via wastewater or household waste. Ask<br />your pharmacist how to dispose of medicines no longer required. These<br />measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Influvac Tetra contains</strong><br />The active substances are:<br />Influenza virus surface antigens (inactivated) (haemagglutinin and<br />neuraminidase) of the following strains*:<br />- A/Victoria/4897/2022 (H1N1) pdm09-like strain (A/Victoria/4897/2022,<br />IVR-238) 15 micrograms HA **<br />- A/Thailand/8/2022 (H3N2)-like strain (A/California/122/2022, SAN-022)<br />15 micrograms HA **<br />- B/Austria/1359417/2021-like strain (B/Austria/1359417/2021, BVR-26)<br />15 micrograms HA **<br />- B/Phuket/3073/2013-like strain (B/Phuket/3073/2013, wild type)<br />15 micrograms HA **<br />per 0.5 ml dose<br />* propagated in fertilised hens&rsquo;eggs from healthy chicken flocks<br />** haemagglutinin<br />This vaccine complies with the World Health Organisation (WHO)<br />recommendation (northern hemisphere) and EU recommendation for the<br />2024/2025 season.<br /><u>The other ingredients are: </u>potassium chloride, potassium dihydrogen<br />phosphate, disodium phosphate dihydrate, sodium chloride, calcium chloride<br />dihydrate, magnesium chloride hexahydrate and water for injections.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Influvac Tetra is a suspension for injection presented in pre-filled glass syringe
(with / without needle) containing
0.5 ml of a colourless clear injection fluid. Each syringe can only be used once.

Pack size of 1 or 10.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong><br />Abbott Biologicals B.V.<br />C.J. van Houtenlaan 36<br />1381 CP Weesp, The Netherlands<br /><strong>Manufacturer:</strong><br />Abbott Biologicals B.V. Veerweg 12<br />8121 AA Olst The Netherlands</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07-2024 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>إنفلوفاك تيترا هو لقاح. يساعد هذا اللقاح على حمايتك أو حماية طفلك من الإنفلونزا، وخاصةً لدى<br />الأشخاص الأكثر عُرضة لخطر المضاعفات المرتبطة بذلك. يوصف إنفلوفاك تيترا في البالغين<br />والأطفال من عمر ٦ شهور. وينبغي أن يعتمد استخدام إنفلوفاك تيترا على التوصيات الرسمية.<br />عندما يتلقى شخص ما اللقاح إنفلوفاك تيترا، فإن الجهاز المناعي (وهو الجهاز الدفاعي الطبيعي<br />بالجسم) سينتج وسيلة حمايته&nbsp;الخاصة (الأجسام المضادة) ضد المرض. ولا يمكن لأي من مكونات<br />اللقاح أن تسبب الإنفلونزا.<br />الإنفلونزا مرض يمكن أن ينتشر سريعًا وينجم عن أنواع مختلفة من السلالات التي يمكن أن تتغير<br />سنويا. ولذلك، قد تحتاج أنت أو طفلك الحصول على التطعيم سنويا. وتكون أقصى خطورة للإصابة<br />بالإنفلونزا خلال الشهور الباردة بين شهري أكتوبر ومارس. إن لم تحصل أنت أو طفلك على التطعيم<br />خلال الخريف، فسيظل معقولًا أن تحصلا على التطعيم حتى الربيع لأنك أنت وطفلك عُرضة لخطر<br />الإصابة بالإنفلونزا حتى ذلك الحين. سيكون في استطاعة طبيبك التوصية بالوقت الأمثل للحصول على<br />التطعيم.<br />سيقوم إنفلوفاك تيترا بوقايتك أنت أو طفلك من سلالات الفيروس الأربعة التي يضمها اللقاح، وذلك بعد<br />الحقن بمدة تتراوح من ۲ إلى ۳ أسابيع تقريبًا.<br />الفترة بين الإصابة بعدوى الإنفلونزا والإصابة بالمرض (فترة حضانة الإنفلونزا) بضعة أيام، لذلك إن<br />تعرضت أنت أو طفلك للإنفلونزا قبل التطعيم أو بعده مباشرةً، فسيظل ممكنًا أن تصاب أنت أو طفلك<br />بالمرض.<br />لن يقي اللقاح من نزلة البرد على الرغم من تشابه بعض أعراضها بالإنفلونزا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>للتأكد من أن إنفلوفاك تيترا يناسبك أنت أو طفلك، من المهم أن تبلغ طبيبك أو الصيدلي أو الممرضة إذا<br />كانت أي من النقاط المبينة أدناه تنطبق عليك أو على طفلك. إن كان هناك ما لا تفهمه، فاطلب من<br />الطبيب أو الصيدلي أو الممرضة إيضاحه لك.<br />لا تستخدم إنفلوفاك تيترا<br />- إن كنت أنت أو طفلك مصابًا بالحساسية تجاه:<br />&bull; المواد الفعالة، أو<br />&bull; أي من مكونات إنفلوفاك تيترا الأخرى (انظر القسم ٦)، أو<br />&bull; أي من المكونات التي قد تكون موجودة بكميات ضئيلة كالبيض (ألبومين البيض (نوع معين من<br />البروتين) أو بروتينات الدجاج)، أو الفورمالدهايد (غاز عديم اللون له رائحة لاذعة)، أو سيتيل<br />ترايميثيل أمونيوم بروميد (مادة كيميائية)، أو بولي سوربات ۸۰ (مادة شبیهة بالزيت تستخدم في<br />المنتجات الطبية والغذائية)، أو جنتاميسين (وهو مضاد حيوييستخدم لعلاج العدوى البكتيریة)<br />- إن أصبت أنت أو طفلك بمرض مصحوب بارتفاع في درجة الحرارة أو بعدوى حادة، فينبغي إرجاء<br />التطعيم إلى ما بعد تعافيك أنت أو طفلك.<br /><strong>تحذيرات واحتياطات</strong><br />ينبغي لك أو لطفلك إبلاغ الطبيب قبل التطعيم إن كنت أنت أو طفلك<br />- ذا استجابة مناعية سيئة (نقص المناعة أو إن كنت تتلقى أدوية تؤثر على الجهاز المناعي).<br />- مشكلة نزفية أو سهولة الإصابة بالكدمات<br />سيقرر الطبيب إن كان ينبغي أن تتلقى أنت أو طفلك اللقاح.<br />يمكن حدوث الإغماء، أو الشعور بالإغماء ، أو غير ذلك من ردّات الفعل المرتبطة بالإجهاد بعد الحقن<br />بأي إبرة، أو حتى قبل ذلك. لذلك أخبر الطبيب أو الممرضة إذا كنت أنت أو طفلك قد سبق تعرضكما<br />إلى هذا النوع من ردة الفعل في حقن سابق.<br />وإذا كنت ستخضع أنت أو طفلك، لأي سبب، لاختبار دم خلال بضعة أيام بعد تطعيم الإنفلونزا، فيرجى<br />إبلاغ الطبيب. وذلك نظرًا لأنه قد لوحظت نتائج إيجابية زائفة لاختبارات الدم لدى القليل من المرضى<br />الذين تم تطعيمهم مؤخرا.<br />وكما هو الحال مع كل اللقاحات، فإن إنفلوفاك تيترا قد لا يقي تمامًا جميع الأشخاص اللذين تلقوا<br />التطعيم.<br />الأدوية الأخرى وإنفلوفاك تيترا<br />- أخبر الطبيب أو الصيدلي أو الممرضة إذا كنت أنت أو طفلك تتناول أو تناولت مؤخرًا أو قد تتناول<br />أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول علیها بدون وصفة طبية.<br />- إنفلوفاك تيترا يمكن أن يعطى في نفس الوقت مع لقاحات باستخدام ساق أخرى أو ذراع آخر. تجدر<br />الإشارة إلى أن الآثار الجانبية قد تكون أكثر شدة.<br />- قد تقل الاستجابة الوقائية (المناعية) في حالة العلاج بدواء مثبط للمناعة، مثل العلاج بالستيرويدات<br />القشرية (هرمونات تنتجها الغدة الكظرية، ويشيع استخدامها للحد من الالتهاب، ويمكن ان تثبط الجهاز<br />المناعي)، أو الأدوية المسممة للخليیا (أدوية تستخدم في العلاج الكيميائي)، أو العلاج الإشعاعي.</p><p><strong>الحمل والرضاعة الطبيعية</strong><br />إن كنتِ حاملًا أو مُرضعة أو تعتقدين أنك حامل أو تخططين للإنجاب، فاستشيري الطبيب أو الصيدلي<br />قبل تلقي هذا الدواء.<br />يمكن استخدام لقاحات الإنفلونزا في كل مراحل الحمل. تتوفر مجموعات بيانات أكبر بشأن السلامة أثناء<br />الثلث الثاني والثالث للحمل، وذلك بالمقارنة بالثلث الأول للحمل، ولكن البيانات المستمدة من استخدام<br />لقاحات الإنفلونزا على النطاق العالمي لا تشير إلى أن اللقاح قد يسبب آثارًا ضارة على الحمل أو<br />الجنين.<br />يمكن استخدام إنفلوفاك تيترا أثناء الرضاعة الطبيعية.<br />سيستطيع الطبيب أو الصيدلي أو الممرضة اتخاذ القرار إن كاني نبغي لكِ أو لطفلك تلقي إنفلوفاك تيترا.<br />استشيري طبيبكِ أو الصيدلي أو الممرضة قبل تناول أي دواء.<br /><strong>القيادة واستخدام الآلات</strong><br />لا يوجد تأثير للقاح إنفلوفاك تيترا على القدرة على القيادة أو استخدام الماكينات أو قد يكون له تأثير<br />ضئيل على ذلك على نحو لا يذكر.<br />يحتوي إنفلوفاك تيترا على الصوديوم والبوتاسيوم<br />يحتوي هذا اللقاح على أقل من ۱ ملليمول ( ۲۳ مجم) للجرعة الواحدة، أي أنه يكاد يكون &quot;خاليا من<br />الصوديوم&quot;.<br />يحتوي هذا اللقاح على البوتاسيوم، بكمية أقل من ۱ ملليمول ( ۳۹ مجم) للجرعة الواحدة، أي أنه يكاد<br />يكون &quot;خاليا من البوتاسيوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>الجرعة</strong><br />يتلقى البالغون جرعة واحدة مقدارها ۰٫٥ مل.<br />الاستخدام في الأطفال<br />يتلقى الأطفال في سن ٦ شهور إلى ۱۷ سنة جرعة واحدة مقدارها ۰٫٥ مل.<br />فيما يخص الأطفال الذين تقل أعمارهم عن ۹ سنوات ، والذين لم يسبق تطعيمهم بلقاح الأنفلونزا<br />الموسمية: يجب إعطاء جرعة ثانية من ۰٫٥ مل بعد فترة ٤ أسابيع على الأقل.<br />فيما يخص الأطفال الذين تقل أعمارهم عن ٦ شهور، لم تثبت السلامة والفاعلية للقاح إنفلوفاك تيترا.<br />طريقة الاستعمال و/أو وسيلته (وسائله)<br />سيعطيك الطبيب أو الممرضة الجرعة الموصى بها من اللقاح بالحقن في العضل أو عميقًا تحت الجلد.<br />إذا كانت لدیك أي أسئلة إضافية عن استخدام هذا المنتج، فاسأل الطبيب أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>٤. الآثار الجانبية المحتملة<br />يمكن أن يتسبب إنفلوفاك تيترا مثل جميع الأدوية في حدوث آثار جانبية، على الرغم من عدم تعرض<br />الجميع لها.<br /><strong>توجه إلى الطبيب فورًا إن أصبت أنت أو طفلك بأي من الآثار الجانبية التالية - فقد تحتاج أنت أو<br />طفلك إلى العناية الطبية العاجلة.</strong><br />حدثت أحيانًا تفاعلات حساسية شديدة (معدل حدوثها غير معروف، خلال استخدام لقاح الإنفلونزا ثلاثي<br />التكافؤ إنفلوفاك)<br />&bull; قد يؤدي ذلك إلى حالة طبية طارئة تتضمن انخفاض ضغط الدم، وتسارع التنفس وضحالته،<br />وتسارع نبض القلب وضعفه، وبرودة الجلد ورطوبته، والدوخة، وهو ما قد يؤدي إلى الانهيار<br />(الصدمة)<br />&bull; تورم يبدو أكثر ظهورًا في الرأس والعنق، بما في ذلك الوجه أو الشفتين أو اللسان أو الحلق أو<br />أي من أجزاء الجسم الأخرى، وھو ما قد يسبب صعوبة البلع أو التنفس (الوذمة الوعائية)<br />خلال التجارب السريرية بخصوص إنفلوفاك تيترا، لوحظت الآثار الجانبية التالية:<br />البالغون وكبار السن:<br /><u>شائعة للغاية: قد تصيب أكثر من شخص من كل ۱۰ أشخاص:</u><br />&bull; الصداع أ<br />&bull; الإجهاد<br />&bull; تفاعلات موضعية: ألم في موضع التطعيم<br />أ في المرضى كبار السن ( ٦۱ سنة أو أكبر) سجلت على أنھا شائعة<br /><u>شائعة: قد تصيب حتى ۱ من كل ۱۰ أشخاص</u>:<br />&bull; التعرق<br />&bull; ألم العضلات (الألم العضلي) وألم المفاصل (الألم المفصلي)<br />&bull; الشعور بالإعياء العام (الوهن) والقشعريرة<br />&bull; تفاعلات موضعية: الاحمرار والتورم والكدمات (التكدم) والتصلب (التيبس) في المنطقة المحيطة<br />بموضع حقن اللقاح<br /><u>غير شائعة: قد تصيب حتى ۱ من كل ۱۰۰ شخص:</u><br />&bull; الحمى<br /><strong>الأطفال (في عمر ٦ شھور إلى ۱۷ سنة):<br />الآثار الجانبية التي حدثت لدى الأطفال في عمر ٦ شھور إلى ۳٥ شهرًا:</strong><br /><u>شائعة للغاية: قد تصيب أكثر من ۱ من كل ۱۰ أشخاص</u>:<br />&bull; النعاس<br />&bull; التعرق<br />&bull; فقدان الشهية<br />&bull; الإسهال والقيء<br />&bull; التهيج/التململ<br />&bull; الحمى<br />&bull; التفاعلات الموضعية: الألم والاحمرار<br /><u>شائعة: قد تصيب حتى ۱ من كل ۱۰ أشخاص:</u><br />&bull; تفاعل موضعي: تورم وتيبس وكدمات<br />٥ سنوات: - الآثار الجانبية التي أصابت الأطفال في عمر ۳<br /><u>شائعة للغاية: قد تصيب أكثر من شخص من كل ۱۰ أشخاص:</u><br />&bull; النُعاس<br />&bull; فقدان الشيهة<br />&bull; التهيج/التململ<br />&bull; تفاعلات موضعية: الألم في موضع التطعيم، والاحمرار والتورم والتصلب (التيبس) في المنطقة<br />المحيطة بموضع حقن اللقاح<br /><u>شائعة: قد تصيب حتى ۱ من كل ۱۰ أشخاص:</u><br />&bull; التعرق<br />&bull; الإسهال/القيء<br />&bull; الحمى<br />&bull; تفاعل موضعي: الكدمات (التكدم)<br />- الآثار الجانبية التي حدثت لدى الأطفال في عمر 6-17 سنة:</p><p>شائعة للغاية: قد تصيب أكثر من شخص من كل ۱۰ أشخاص:<br />&bull; الصداع<br />&bull; الغثيان وألم البطن والإسهال والقيء<br />&bull; ألم العضلات (الألم العضلي)<br />&bull; الإجهاد، والإحساس بالإعياء العام (الوهن)<br />&bull; تفاعلات موضعية: الألم في موضع التطعيم، والاحمرار والتورم والتصلب (التيبس) في المنطقة<br />المحيطة بموضع حقن اللقاح<br />شائعة: قد تصيب حتى ۱ من كل ۱۰ أشخاص:<br />&bull; التعرق<br />&bull; ألم المفاصل (الألم المفصلي)<br />&bull; الحمى<br />&bull; القشعريرة<br />&bull; تفاعل موضعي: الكدمات (التكدم)</p><p><strong>كل الفئات العمرية</strong><br />في كل الفئات العمرية، حدثت أغلب التفاعلات المذكورة أعلاه عادةً خلال أول ۳ أيام من التطعيم،<br />وزالت من تلقاء نفسها خلال ۱ إلى ۳ أيام من بدايتها. وقد كانت حدة تلك التفاعلات بسيطة بصفة عامة.<br />وبالإضافة إلى الآثار الجانبية المذكورة أعلاه، حدثت الآثار الجانبية التالية أحيانًا خلال الاستخدام العام<br />للقاح الإنفلونزا ثلاثي التكافؤ إنفلوفاك:<br />معدل حدوثها غير معروف (لا يمكن تقديره من واقع البيانات المتاحة):<br />&bull; التفاعلات الجلدية التي قد تنتشر في أنحاء الجسم بما في ذلك حكة الجلد (الحكة الجلدية والشرى)<br />والطفح الجلدي<br />&bull; التهاب الأوعية الدموية وهو ما قد يؤدي إلى الطفح الجلدي (الالتهاب الوعائي) وقد يؤدي في حالات<br />شديدة النُدرة إلى مشكلات كلوية مؤقتة.<br />&bull; الألم في موضع مسار العصب (الألم العصبي)، وعيوب الإحساس باللمس والألم والحرارة والبرودة،<br />والنوبات (التشنجات) المصاحبة للحمى، والاضطرابات العصبية التي قد تؤدي إلى تيبس العنق<br />والارتباك والتنميل والألم وضعف الذراعين أو الساقين، وفقدان التوازن، وفقدان ردود الأفعال، وشلل<br />جزء من الجسم أو الجسم بالكامل (التهاب الدماغ والنخاع الشوكي (الالتهاب الدماغي النخاعي)،<br />والتهاب الأعصاب (الالتهاب العصبي)، والتهاب الأعصاب مع بداية مفاجئة لذلك (متلازمة غيلان<br />باریه))<br />&bull; الانخفاض المؤقت في أعداد أنواع معينة من الجسيمات الموجودة في الدم، والتي تسمى صفائح الدم،<br />ويمكن أن يؤدي انخفاض أعدادها إلى فرط الإصابة بالكدمات أو النزيف (قلة صفائح الدم العابرة)،<br />والتورم المؤقت في غدد العنق أو الإبط أو المنطقة الأربية (اعتلال العقد اللمفاوية العابر)<br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا أُصبت أنت أو طفلك بأي آثار جانبیة، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يشمل ذلك أي<br />آثار جانبية محتملة غير مدرجة في هذه النشرة.</p><p>للإبلاغ عن الأعراض الجانبية<br />(NPC) - المركز الوطني للتیقظ والسلامة الدوائية<br />+۹٦٦-۱۱-۲۰٥- فاكس ۷٦٦۲ o<br />مركز الاتصال: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : البريد الإلكتروني o<br />https://ade.sfda.gov.sa : الموقع الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />يحفظ بعيدًا عن مرأى الأطفال ومتناولهم.<br />لا تستخدم إنفلوفاك تيترا بعد تاريخ انتهاء الصلاحية المذكور على العبوة الكرتونية. يشير تاريخ انتهاء<br />الصلاحية إلى آخر يوم في ذلك الشهر.<br />يخزَّن إنفلوفاك تيترا في الثلاجة (بين + ۲ إلى + ۸ درجة مئوية). لا تقم بتجميد المنتج.<br />يخزَّن المنتج في عبوته الأصلية لحمايته من الضوء.<br />لا يجوز التخلص من الأدوية عن طريق الصرف الصحي أو نفايات المنزل. اسأل الصيدلي عن كيفية<br />التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المواد الفعالة ھي:<br />المستضدات السطحية لفیروس الإنفلونزا (مُعطَّلة) (هيماجلوتينين ونورامينيداز) للسلالات التالية*:<br />A/Victoria/4897/2022 (H1N1) pdm - السلالة المشابهة ل 09<br />۱٥ ميكروجرام من هيماجلوتينين** (A/Victoria/4897/2022, IVR-238)<br />A/Thailand/8/2022 (H3N2) (A/California/122/ - السلالة المشابهة ل , 2022<br />۱٥ ميكروجرام من هيماجلوتينين** S AN-022)<br />B/Austria/1359417/ - السلالة المشابهة ل 2021<br />۱٥ ميكروجرام من هيماجلوتينين** (B/Austria/1359417/2021, BVR-26)<br />B/Phuket/3073/ - السلالة المشابهة ل 2013<br />۱٥ ميكروجرام من هيماجلوتينين** (B/Phuket/3073/2013, wild type)<br />لكل جرعة مقدارها ۰٫٥ مل<br />* تكاثرت في بيض الدجاج المُخصَّب من أسراب دجاج سليمة<br />**هيماجلوتينين<br />نصف الكرة الأرضية الشمالي) وتوصية ) (WHO) يتفق هذا اللقاح مع توصية منظمة الصحة العالمية<br />. ۲۰۲٥/ لموسم ۲۰۲٤ (EU) الاتحاد الأوروبي<br />تتضمن المكونات الأخرى مايلي: كلوريد البوتاسيوم، وفوسفات البوتاسيوم ثنائي الهيدروجین، وثنائي<br />هيدرات الفوسفات ثنائي الصوديوم، وكلوريد الصوديوم، وثنائي هيدرات كلوريد الكالسيوم، وسداسي<br />هيدرات كلوريد الماغنيسيوم، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>إنفلوفاك تيترا هو معلق للحقن يتوفر في شكل محقنة زجاجية مسبقة التعبئة (مزودة بإبرة أو بدونها)<br />تحتوي على ۰٫٥ مل من سائل الحقن الشفاف عديم اللون. لا يمكن استخدام كل محقنة سوى لمرة واحدة<br />فقط.<br />. حجم العبوة ۱ أو ۱۰<br />قد لا تتوفر جميع أحجام العبوات في الأسواق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك تصريح التسويق:<br />Abbott Biologicals B.V.<br />C.J. van Houtenlaan 36<br />1381 CP Weesp, The Netherlands<br />الجهة المصنعة:<br />Abbott Biologicals B.V.<br />Veerweg 12<br />8121 AA Olst<br />The Netherlands</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07-2024 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Influvac® Tetra, suspension for injection in pre-filled syringe 0.5 ml (influenza vaccine, surface antigen, inactivated).   
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Influenza virus surface antigens (inactivated) (haemagglutinin and neuraminidase) of the following strains*:  
- A/Victoria/4897/2022 (H1N1)pdm09-like strain
(A/Victoria/4897/2022, IVR-238)
- A/Thailand/8/2022 (H3N2)-like strain	15 micrograms HA **
(A/California/122/2022, SAN-022)
- B/Austria/1359417/2021-like strain	15 micrograms HA **
(B/Austria/1359417/2021, BVR-26) - B/Phuket/3073/2013-like strain	15 micrograms HA **
(B/Phuket/3073/2013, wild type)

*propagated in fertilised hens’ eggs from healthy chicken flocks ** haemagglutinin.	15 micrograms HA ** per 0.5 ml dose
This vaccine complies with the World Health Organisation (WHO) recommendation (northern hemisphere) and EU recommendation for the 2024/2025 season.  
  
For a full list of excipients see section 6.1.  
Influvac Tetra may contain traces of eggs (such as ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80 or gentamicin, which are used during the manufacturing process (see section 4.3).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for injection in pre-filled syringe.
A colourless clear liquid.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prophylaxis of influenza, especially those who run an increased risk of associated complications.&nbsp;</p><p>Influvac Tetra is indicated in adults and children from 6 months of age.</p><p>The use of Influvac Tetra should be based on official recommendations.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Adults: 0.5 ml.&nbsp;</p><p><u>Paediatric population</u></p><p>Children from 6 months to 17 years of age: 0.5 ml.</p><p>Children less than 9 years of age, who have not previously been vaccinated with a seasonal influenza vaccine: a second dose of 0.5 ml should be given after an interval of at least 4 weeks.</p><p>Infants less than 6 months of age: the safety and efficacy of Influvac Tetra have not been established.</p><p><u>Method of Administration</u></p><p>Immunisation should be carried out by intramuscular or deep subcutaneous injection.</p><p>The preferred sites for intramuscular injection are the anterolateral aspect of the thigh (or the deltoid muscle if muscle mass is adequate) in children 6 months through 35 months of age, or the deltoid muscle in children from 36 months of age and adults.</p><p>Precautions to be taken before handling or administrating the medicinal product:</p><p>For instructions for preparation of the medicinal product before administration, see section 6.6.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polysorbate 80 or gentamicin.   
Immunisation shall be postponed in patients with febrile illness or acute infection.  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.&nbsp;&nbsp;&nbsp;</p><p>Influvac Tetra should under no circumstances be administered intravascularly.&nbsp;</p><p>As with other vaccines administered intramuscularly, Influvac Tetra should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.</p><p>Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions can occur following, or even before, any vaccination as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.</p><p>Influvac Tetra is not effective against all possible strains of influenza virus. Influvac Tetra is intended to provide protection against those strains of virus from which the vaccine is prepared and to closely related strains.</p><p>As with any vaccine, a protective immune response may not be elicited in all vaccinees.</p><p>Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.&nbsp;</p><p>Interference with serological testing: see section 4.5.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &lsquo;sodium- free&rsquo;. This medicine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially &ldquo;potassium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. If Influvac Tetra is given at the same time as other vaccines, immunisation should be carried out on separate limbs. It should be noted that the adverse reactions may be intensified.&nbsp;</p><p>The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.&nbsp;</p><p>Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed. The Western Blot technique disproves the false-positive ELISA test results. The transient false-positive reactions could be due to the IgM response by the vaccine.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Inactivated influenza vaccines can be used in all stages of pregnancy. Larger datasets on safety are available for the second and third trimester, compared with the first trimester; however, data from worldwide use of influenza vaccine do not indicate any adverse foetal and maternal outcomes attributable to the vaccine.</p><p><u>Breast-feeding</u></p><p>Influvac Tetra may be used during breast-feeding.&nbsp;</p><p><u>Fertility</u></p><p>No fertility data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Influvac Tetra has no or negligible influence on the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>a. Summary of the safety profile</em></p><p>The safety of Influvac Tetra was assessed in three clinical trials.</p><p>In two clinical studies, healthy adults 18 years of age and older, and healthy children 3 to 17 years of age were administered Influvac Tetra or trivalent influenza vaccine Influvac.</p><p>In a third study, the safety of Influvac Tetra was assessed in healthy children from 6 months to 35 months of age administered Influvac Tetra or a non-influenza vaccine control.</p><p>In both children studies, children from 6 months to 8 years of age received one or two doses of Influvac Tetra depending on their influenza vaccination history.</p><p>Most reactions usually occurred within the first 3 days following vaccination and resolved spontaneously within 1 to 3 days after onset. The intensity of these reactions was generally mild.</p><p>In all age groups, the most frequently reported local adverse reaction after vaccination observed in the clinical studies for Influvac Tetra was vaccination site pain<em>.</em></p><p>The most frequently reported general adverse reactions after vaccination observed in the clinical studies for Influvac Tetra in adults and children from 6 to 17 years of age were fatigue and headache, and for children from 3 to 5 years of age drowsiness, irritability and loss of appetite.</p><p>The most frequently reported general adverse reactions after vaccination observed in the clinical studies for Influvac Tetra in children from 6 months to 35 months of age were irritability/fussiness.</p><p>Similar rates of solicited adverse reactions were observed in recipients of Influvac Tetra and trivalent influenza vaccine Influvac.&nbsp;</p><p>The rates of solicited systemic adverse reactions were similar in recipients of Influvac Tetra and the non-influenza vaccine, whereby the rates of solicited local adverse reactions were lower in recipients of Influvac Tetra.</p><p><em>b. Tabulated summary of adverse reactions</em></p><p>The following undesirable effects are considered at least possibly related to Influvac Tetra and have either been observed during the clinical trials with Influvac Tetra or are resulting from post-marketing experience with Influvac Tetra and/or the trivalent influenza vaccine Influvac.</p><p>The following frequencies apply:&nbsp;&nbsp;</p><p>very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1,000, &lt;1/100); and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data).</p><p><strong><u>Adults and elderly&nbsp;</u></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:649px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Adverse Reactions Reported with Influvac Tetra</strong></p></td></tr><tr><td><p><strong>MedDRA System </strong></p><p><strong>Organ Class</strong></p></td><td><p><strong>Very common</strong></p><p><strong>&ge; 1/10</strong></p></td><td><p><strong>Common</strong></p><p><strong>&ge; 1/100 to &lt; 1/10</strong></p></td><td><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1,000 to &lt; 1/100</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong><sup>a</sup></p><p><strong>(cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient thrombocytopenia, transient lymphadenopathy</p></td></tr><tr><td><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reactions, in rare</p><p>cases leading to shock, angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neuralgia, paraesthesia, febrile convulsions, neurological disorders, such as encephalomyelitis, neuritis and Guillain Barr&eacute;</p><p>syndrome</p></td></tr><tr><td><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasculitis associated in very rare cases with</p><p>transient renal involvement&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>subcutaneous tissue disorders&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sweating</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Generalised skin reactions including pruritus, urticaria or non-specific rash</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia, arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue</p><p>Local reaction:</p><p>pain</p></td><td style="vertical-align:top"><p>Malaise, shivering Local reactions: redness, swelling, ecchymosis, induration</p></td><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>a</p><p>Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>b In elderly adults (&ge; 61 years) reported as common</p></td></tr></tbody></table><p><strong><em>Paediatric population</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:661px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong><u>Children (6 months to 17 years of age) </u></strong><strong>Adverse Reactions Reported with Influvac Tetra</strong></p></td></tr><tr><td><p><strong>MedDRA System </strong></p><p><strong>Organ Class</strong></p></td><td><p><strong>Very common</strong></p><p><strong>&ge; 1/10</strong></p></td><td><p><strong>Common</strong></p><p><strong>&ge; 1/100 to &lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1,000 to </strong></p><p><strong>&lt; 1/100</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong><sup>a</sup></p><p><strong>(cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Transient thrombocytopenia, transient lymphadenopathy</p></td></tr><tr><td><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reactions, in rare</p><p>cases leading to shock, angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache<sup>c</sup></p><p>Drowsiness<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Neuralgia, paraesthesia, febrile convulsions, neurological disorders, such as encephalomyelitis, neuritis and Guillain Barr&eacute;</p><p>syndrome</p></td></tr><tr><td><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasculitis associated in very rare cases with</p><p>transient renal involvement&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>subcutaneous tissue disorders&nbsp;</p></td><td style="vertical-align:top"><p>Sweating<sup>f</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Generalised skin reactions including pruritus, urticaria or non-specific rash</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Appetite loss<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea<sup>c</sup>, abdominal pain<sup>c</sup>, diarrhoea<sup>e</sup>, vomiting<sup>e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Irritability/fussiness<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia<sup>c</sup></p></td><td style="vertical-align:top"><p>Arthralgia<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue<sup>c</sup>, fever<sup>f </sup>malaise<sup>c</sup></p><p>Local reactions: pain, redness, swelling<sup>d</sup>, induration<sup>d</sup></p></td><td style="vertical-align:top"><p>Shivering<sup>c </sup>Local reaction:</p><p>ecchymosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup>Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure</p><p><sup>b</sup>Reported in children 6 months to 5 years of age</p><p><sup>c</sup>Reported in children 6 to 17 years of age</p><p><sup>d</sup>Reported as common in children 6 to 35 months of age</p><p><sup>e</sup>Reported as common in children 3 to 5 years of age</p><p><sup>f</sup>Reported as common in children 3 to 17 years of age</p></td></tr></tbody></table><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><table border="1" cellspacing="0" cellpadding="0" style="width:384px"><tbody><tr><td style="vertical-align:top; width:381px"><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o </strong>SFDA Call Center: 19999</p><p><strong>o</strong><strong> </strong>E-mail: npc.drug@sfda.gov.sa</p><p><strong>o</strong><strong> </strong>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdosage is unlikely to have any untoward effect.&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Influenza vaccine, ATC Code: J07BB02.</p><p><u>Mechanism of action:</u></p><p>Influvac Tetra provides active immunisation against four influenza virus strains: an A/(H1N1) strain, an A/(H3N2) strain, and two B strains (one from each lineage; B/(Victoria) and B/(Yamagata)). Influvac Tetra, manufactured according to the same process as trivalent influenza vaccine Influvac, induces humoral antibodies against the haemagglutinins. These antibodies neutralise influenza viruses. Specific levels of hemagglutination-inhibition (HI) antibody titer post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness but the HI antibody titers have been used as a measure of vaccine activity.</p><p>An immune response is generally obtained within 2 to 3 weeks. The duration of postvaccinal immunity to homologous strains or to strains closely related to the vaccine strains varies but is usually 6-12 months.&nbsp;</p><p><u>Pharmacodynamic effects:</u></p><p><u>Efficacy of Influvac Tetra in children 6 - 35 months of age:</u></p><p>The efficacy of Influvac Tetra was evaluated in a randomized, observer-blind, non-influenza vaccine-controlled study (INFQ3003) conducted during 3 influenza seasons 2017 to 2019 in Europe and Asia. Healthy subjects aged 6 - 35 months received two doses of Influvac Tetra (N=1005) or non-influenza control vaccine (N=995) approximately 28 days apart. The efficacy of Influvac Tetra was assessed for the prevention of reverse transcription polymerase chain reaction (RT-PCR) confirmed influenza A and/or B disease due to any influenza strain. All RT-PCR-positive specimens were further tested for viability in cell culture and to determine whether the circulating viral strains matched those in the vaccine.</p><p>Table: Efficacy in children 6 &ndash; 35 months of age</p><table border="0" cellspacing="0" cellpadding="0" style="width:551px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Influvac Tertra</p><p>N=1005</p></td><td style="vertical-align:top"><p>Non-influenza</p><p>control-vaccine</p><p>N=995</p></td><td style="vertical-align:top"><p>Vaccine efficacy</p><p>(95% CI)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory-confirmed influenza caused by:</strong></p></td><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <strong>Any influenza A or B strain</strong></p></td><td style="vertical-align:top"><p>59</p></td><td style="vertical-align:top"><p>117</p></td><td style="vertical-align:top"><p>0.54 (0.37 - 0.66)</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <strong>Culture confirmed vaccine matching strains</strong></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>0.68 (0.45 - 0.81)</p></td></tr></tbody></table><p>Vaccine efficacy: proportion of influenza cases prevented by the vaccination</p><p>N=number of subjects vaccinated n=number of influenza cases</p><p>CI=confidence interval</p><p><u>Immunogenicity of Influvac Tetra:</u></p><p>Clinical studies performed in adults of 18 years of age and older (INFQ3001) and children of 3 to 17 years of age (INFQ3002) assessed the safety and immunogenicity of Influvac Tetra and its noninferiority to trivalent influenza vaccine Influvac for the postvaccination HI Geometric mean antibody titer (GMT).</p><p>In both studies the immune response elicited by Influvac Tetra against the three strains in common was non-inferior to trivalent influenza vaccine Influvac. Influvac Tetra elicited a superior immune response against the additional B strain included in Influvac Tetra compared to trivalent influenza vaccine Influvac.</p><p><u>Adults 18 years of age and older:</u></p><p>In clinical studyINFQ3001, 1,535 adults of 18 years of age and older received a single dose of Influvac Tetra and 442 subjects received a single dose of trivalent Influvac:</p><p><u>Table: Post-vaccination GMT and Seroconversion rates</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:653px"><tbody><tr><td style="vertical-align:top"><p><strong>Adults 18 &ndash; 60 years of age</strong></p></td><td style="vertical-align:top"><p>Influvac Tetra</p><p>N=768</p></td><td style="vertical-align:top"><p>Influvac<sup>1</sup></p><p>N=112</p></td><td style="vertical-align:top"><p>Influvac<sup>2</sup></p><p>N=110</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>GMT (95% confidence interval)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H1N1</strong></p></td><td style="vertical-align:top"><p>272.2&nbsp; (248.0 , 298.8)</p></td><td style="vertical-align:top"><p>304.4&nbsp; (235.1 , 394.1)</p></td><td style="vertical-align:top"><p>316.0&nbsp; (245.1 , 407.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H3N2</strong></p></td><td style="vertical-align:top"><p>442.4&nbsp; (407.6 , 480.2)</p></td><td style="vertical-align:top"><p>536.5&nbsp; (421.7 , 682.6)</p></td><td style="vertical-align:top"><p>417.0&nbsp; (323.7 , 537.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Yamagata)<sup>3</sup></strong></p></td><td style="vertical-align:top"><p>162.5&nbsp; (147.8 , 178.7)</p></td><td style="vertical-align:top"><p>128.7&nbsp; (100.3 , 165.2)</p></td><td style="vertical-align:top"><p>81.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (60.7 , 109.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Victoria)<sup>4</sup></strong></p></td><td style="vertical-align:top"><p>214.0&nbsp; (195.5 , 234.3)</p></td><td style="vertical-align:top"><p>85.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (62.6 , 115.6)</p></td><td style="vertical-align:top"><p>184.7&nbsp; (139.0 , 245.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Seroconversion Rates (95% confidence interval)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H1N1</strong></p></td><td style="vertical-align:top"><p>59.4%&nbsp; (55.8% , 62.9%)</p></td><td style="vertical-align:top"><p>65.5%&nbsp; (55.8% , 74.3%)</p></td><td style="vertical-align:top"><p>64.8%&nbsp; (55.0% , 73.8%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H3N2</strong></p></td><td style="vertical-align:top"><p>51.3%&nbsp; (47.7% , 54.9%)</p></td><td style="vertical-align:top"><p>61.6%&nbsp; (51.9% , 70.6%)</p></td><td style="vertical-align:top"><p>55.5%&nbsp; (45.7% , 64.9%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Yamagata)<sup>3</sup></strong></p></td><td style="vertical-align:top"><p>59.2%&nbsp; (55.7% , 62.8%)</p></td><td style="vertical-align:top"><p>58.7%&nbsp; (48.9% , 68.1%)</p></td><td style="vertical-align:top"><p>40.9%&nbsp; (31.6% , 50.7%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Victoria)<sup>4</sup></strong></p></td><td style="vertical-align:top"><p>70.2%&nbsp; (66.8% , 73.4%)</p></td><td style="vertical-align:top"><p>51.4%&nbsp; (41.6% , 61.1%)</p></td><td style="vertical-align:top"><p>66.4%&nbsp; (56.7% , 75.1%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Elderly 61 years of age and older</strong></p></td><td style="vertical-align:top"><p>Influvac Tetra</p><p>N=765</p></td><td style="vertical-align:top"><p>Influvac<sup>1</sup></p><p>N=108</p></td><td style="vertical-align:top"><p>Influvac<sup>2</sup></p><p>N=110</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>GMT (95% confidence interval)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H1N1</strong></p></td><td style="vertical-align:top"><p>127.2&nbsp; (114.9 , 140.9)</p></td><td style="vertical-align:top"><p>142.4&nbsp; (107.6 , 188.3)</p></td><td style="vertical-align:top"><p>174.2&nbsp; (135.9 , 223.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H3N2</strong></p></td><td style="vertical-align:top"><p>348.5&nbsp; (316.8 , 383.5)</p></td><td style="vertical-align:top"><p>361.5&nbsp; (278.3 , 469.6)</p></td><td style="vertical-align:top"><p>353.4&nbsp; (280.7 , 445.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Yamagata)<sup>3</sup></strong></p></td><td style="vertical-align:top"><p>63.7&nbsp;&nbsp; (57.7 , 70.4)</p></td><td style="vertical-align:top"><p>57.4&nbsp;&nbsp; (43.6 , 75.7)</p></td><td style="vertical-align:top"><p>27.3&nbsp; (20.7 , 36.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Victoria)<sup>4</sup></strong></p></td><td style="vertical-align:top"><p>109.4&nbsp;&nbsp; (98.1 , 122.0)</p></td><td style="vertical-align:top"><p>48.0&nbsp;&nbsp; (34.6 , 66.6)</p></td><td style="vertical-align:top"><p>106.6&nbsp; (79.7 , 142.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Seroconversion Rates (95% confidence interval)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H1N1</strong></p></td><td style="vertical-align:top"><p>50.3%&nbsp; (46.7% , 54.0%)</p></td><td style="vertical-align:top"><p>56.6%&nbsp; (46.6% , 66.2%)</p></td><td style="vertical-align:top"><p>58.2%&nbsp; (48.4% , 67.5%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H3N2</strong></p></td><td style="vertical-align:top"><p>39.3%&nbsp; (35.8% , 42.9%)</p></td><td style="vertical-align:top"><p>44.4%&nbsp; (34.9% , 54.3%)</p></td><td style="vertical-align:top"><p>43.6%&nbsp; (34.2% , 53.4%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Yamagata)<sup>3</sup></strong></p></td><td style="vertical-align:top"><p>49.9%&nbsp; (46.2% , 53.5%)</p></td><td style="vertical-align:top"><p>46.2%&nbsp; (36.5% , 56.2%)</p></td><td style="vertical-align:top"><p>30.0%&nbsp; (21.6% , 39.5%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Victoria)<sup>4</sup></strong></p></td><td style="vertical-align:top"><p>53.6%&nbsp; (50.0% , 57.2%)</p></td><td style="vertical-align:top"><p>25.0%&nbsp; (17.2% , 34.3%)</p></td><td style="vertical-align:top"><p>55.6%&nbsp; (45.7% , 65.1%)</p></td></tr></tbody></table><p>N= number of subjects included in immunogenicity analysis</p><p><sup>1</sup>containing A/H1N1, A/H3N2 and B (Yamagata lineage)</p><p><sup>2</sup>containing A/H1N1, A/H3N2 and B (Victoria lineage)</p><p><sup>3</sup>recommended B strain by WHO for the season 2014-2015 NH for trivalent vaccines</p><p><sup>4</sup>additional recommended B strain by WHO for season 2014-2015 NH for quadrivalent vaccines</p><p><strong><em>Paediatric population</em></strong></p><p><u>Children 3 - 17 years of age:</u></p><p>In clinical study INFQ3002, 402 children of 3 to 17 years of age received one or two doses of Influvac Tetra and 798 children received one or two doses of trivalent Influvac based on their influenza vaccination history.</p><p><u>Table: Seroconversion rates</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:647px"><tbody><tr><td style="vertical-align:top"><p><strong>Children&nbsp; 3 -</strong></p><p><strong>17 years of age</strong></p></td><td style="vertical-align:top"><p>Influvac Tetra</p><p>N=396</p></td><td style="vertical-align:top"><p>Influvac<sup>1</sup></p><p>N=389</p></td><td style="vertical-align:top"><p>Influvac<sup>2</sup></p><p>N=399</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Seroconversion Rates (95% confidence interval)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H1N1</strong></p></td><td style="vertical-align:top"><p>60.1%&nbsp; (55.1% , 65.0%)</p></td><td style="vertical-align:top"><p>61.8%&nbsp; (56.7% , 66.6%)</p></td><td style="vertical-align:top"><p>59.1%&nbsp; (54.1% , 64.0%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H3N2</strong></p></td><td style="vertical-align:top"><p>80.6%&nbsp; (76.3% , 84.3%)</p></td><td style="vertical-align:top"><p>82.4%&nbsp; (78.3% , 86.1%)</p></td><td style="vertical-align:top"><p>80.7%&nbsp; (76.5% , 84.5%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Yamagata)<sup>3</sup></strong></p></td><td style="vertical-align:top"><p>79.3%&nbsp; (75.0% , 83.2%)</p></td><td style="vertical-align:top"><p>73.1%&nbsp; (68.4% , 77.5%)</p></td><td style="vertical-align:top"><p>28.1%&nbsp; (23.7% , 32.8%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Victoria)<sup>4</sup></strong></p></td><td style="vertical-align:top"><p>76.5%&nbsp; (72.0% , 80.6%)</p></td><td style="vertical-align:top"><p>39.5%&nbsp; (34.6% , 44.6%)</p></td><td style="vertical-align:top"><p>72.7%&nbsp; (68.0% , 77.0%)</p></td></tr></tbody></table><p>N= number of subjects included in immunogenicity analysis</p><p><sup>1</sup>containing A/H1N1, A/H3N2 and B (Yamagata lineage)</p><p><sup>2</sup>containing A/H1N1, A/H3N2 and B (Victoria lineage)</p><p><sup>3</sup>recommended B strain by WHO for the season 2016-2017 NH for trivalent vaccines</p><p><sup>4</sup>additional recommended B strain by WHO for season 2016-2017 NH for quadrivalent vaccines</p><p><u>Children 6 months - 35 months of age:</u></p><p>In clinical study INFQ3003 the immunogenicity of Influvac Tetra was evaluated in terms of seroconversion rates across 3 influenza seasons.</p><p><u>Table: Seroconversion rates</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td style="vertical-align:top"><p><strong>Children 6 35 months of age</strong></p></td><td style="vertical-align:top"><p>Influenza season</p><p>NH 2017-2018<sup>1</sup></p><p>N=348</p></td><td style="vertical-align:top"><p>Influenza season</p><p>NH 2018-2019<sup>1</sup></p><p>N=359</p></td><td style="vertical-align:top"><p>Influenza season</p><p>SH 2019<sup>1</sup></p><p>N=225</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Seroconversion Rates (95% confidence interval)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H1N1</strong></p></td><td style="vertical-align:top"><p>74.4%&nbsp;&nbsp; (69.5% , 78.9%)</p></td><td style="vertical-align:top"><p>76.0%&nbsp;&nbsp; (71.3% , 80.4%)</p></td><td style="vertical-align:top"><p>69.8%&nbsp;&nbsp; (63.3% , 75.7%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>A/H3N2</strong></p></td><td style="vertical-align:top"><p>92.5%&nbsp;&nbsp; (89.2% , 95.0%)</p></td><td style="vertical-align:top"><p>86.6%&nbsp;&nbsp; (82.7% , 90.0%)</p></td><td style="vertical-align:top"><p>86.2%&nbsp;&nbsp; (81.0% , 90.4%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Yamagata)</strong></p></td><td style="vertical-align:top"><p>35.5%&nbsp;&nbsp; (30.4% , 40.8%)</p></td><td style="vertical-align:top"><p>56.0%&nbsp;&nbsp; (50.7% , 61.2%)</p></td><td style="vertical-align:top"><p>16.9%&nbsp;&nbsp; (12.2% , 22.4%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>B (Victoria)</strong></p></td><td style="vertical-align:top"><p>26.5%&nbsp;&nbsp; (21.9% , 31.5%)</p></td><td style="vertical-align:top"><p>65.2%&nbsp;&nbsp; (60.0% , 70.1%)</p></td><td style="vertical-align:top"><p>47.6%&nbsp;&nbsp; (40.9% , 54.3%)</p></td></tr></tbody></table><p>N= number of subjects included in immunogenicity analysis</p><p><sup>1</sup>containing recommended strains by WHO for respective season for quadrivalent vaccines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data revealed no special hazard for humans based on conventional studies of repeat dose and local toxicity, reproductive and developmental toxicity and safety pharmacology studies.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Potassium chloride</p><p>-&nbsp;&nbsp; Potassium dihydrogen phosphate</p><p>-&nbsp;&nbsp; Disodium phosphate dihydrate</p><p>-&nbsp;&nbsp; Sodium chloride</p><p>-&nbsp;&nbsp; Calcium chloride dihydrate</p><p>-&nbsp;&nbsp; Magnesium chloride hexahydrate</p><p>&nbsp;- Water for injections&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 year.  
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator <strong>(</strong>2&deg;C - 8&deg;C<strong>)</strong>. Do not freeze.&nbsp;&nbsp;</p><p>Store in the original package in order to protect from light.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.5 ml suspension for injection in pre-filled syringe with or without needle (glass, type I), pack of 1 or 10.&nbsp;</p><p><em>Not all pack sizes may be marketed.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The vaccine should be allowed to reach room temperature before use.&nbsp;&nbsp; Shake before use. Inspect visually prior to administration.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Biologicals B.V.  
C.J. van Houtenlaan 36  
1381 CP Weesp,   
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07-2024 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>